Maintenance of initial therapeutic response of at least 30% pain intensity reduction over baseline and continued treatment at 13 or 26 weeks (equivalent to 'moderate benefit') · adults with fibromyalgia enrolled in EERW studies
1 finding from 1 review
Change in burn‐related pruritus (VAS) ( · people with postburn pruritus
Pregabalin showed no clear difference in change in burn‐related pruritus (VAS) ( compared with cetirizine with pheniramine maleate (antihistamine) (low certainty).
1 finding from 1 review
Adverse effects: drowsiness (gabapentin alone) · people with postburn pruritus
Pregabalin may leads to lower adverse events (drowsiness) compared with cetirizine with pheniramine maleate (antihistamine) (low certainty).
1 finding from 1 review
Pain · people with postburn pruritus
The review found no eligible studies for this question.
1 finding from 1 review
Benzodiazepine discontinuation, end of intervention · adults who withdraw from chronic benzodiazepine use
It is very uncertain whether pregabalin changes benzodiazepine discontinuation, end of intervention compared with placebo (very low certainty).
1 finding from 1 review
Benzodiazepine discontinuation, longest · adults who withdraw from chronic benzodiazepine use
1 finding from 1 review
Benzodiazepine withdrawal symptoms, end of intervention · adults who withdraw from chronic benzodiazepine use
1 finding from 1 review
Benzodiazepine withdrawal symptoms, longest · adults who withdraw from chronic benzodiazepine use
1 finding from 1 review
Adverse events · children and adolescents with chronic non‐cancer pain
1 finding from 1 review
Serious adverse events · children and adolescents with chronic non‐cancer pain
1 finding from 1 review
Withdrawals due to adverse events · children and adolescents with chronic non‐cancer pain
1 finding from 1 review
Participant‐reported pain relief of 30% or greater · children and adolescents with chronic non‐cancer pain
1 finding from 1 review
Participant‐reported pain relief of 50% or greater · children and adolescents with chronic non‐cancer pain
1 finding from 1 review
Patient Global Impression of Change much or very much improved · children and adolescents with chronic non‐cancer pain
1 finding from 1 review
At least 50% reduction in pain · patients with fibromyalgia
Pregabalin leads to higher 50% pain reduction compared with placebo at end of treatment (high certainty).
1 finding from 1 review
Patient Global Impression of Change much or very much improved · patients with fibromyalgia
Pregabalin leads to higher patient Global Impression of Change of 'much' or 'very much' improved compared with placebo at end of treatment (high certainty).
1 finding from 1 review
Fatigue · patients with fibromyalgia
1 finding from 1 review
Participant‐reported sleep problems (scale: 0 to 28; higher scores indicate more sleep problems) · patients with fibromyalgia
1 finding from 1 review
Withdrawals due to adverse events · patients with fibromyalgia
Pregabalin leads to higher withdrawal due to adverse events compared with placebo at end of treatment (high certainty).
1 finding from 1 review
Serious adverse events · patients with fibromyalgia
Pregabalin showed no clear difference in serious adverse events compared with placebo at end of treatment (moderate certainty).
1 finding from 1 review